Clinical trials · Massachusetts
Lung Cancer (NSCLC) clinical trials in Massachusetts
We’re tracking 109 recruiting lung cancer (nsclc) studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT04900935Recruiting
Survivorship and palliative care planning for metastatic lung cancer
This study tests a more patient-centered way to plan survivorship care and comfort (palliative) care for people with metastatic lung cancer. It may help you get support that matches your goals, especially alongside your current targeted treatment.
Boston, MassachusettsAges 18 years+ - NCT04981119Recruiting
Test apheresis for CAR T manufacturing in HLA-A2 solid tumors
This trial studies how a process called apheresis is used to make CAR T cells for people with certain solid tumors. It is designed for tumors that have lost a specific immune marker (HLA-A*02), which may affect how well CAR T therapies work.
Boston, MassachusettsAges 18 years+ - NCT05265429Recruiting
Study of young people’s lung cancer biology
This study looks at biological samples from people diagnosed with lung cancer at age 45 or younger. It may help researchers understand how young lung cancers differ, which could guide future treatments.
Boston, MassachusettsAges 15 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Boston, MassachusettsAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Boston, MassachusettsAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Worcester, MassachusettsAges 18 years+ - NCT05786924RecruitingPhase 1/Phase 2
Targeted cancer drug study for RAS/RAF mutation-positive tumors
This Phase 1/2 study tests S241656 (a targeted cancer medicine) in people whose cancers have certain “RAS/RAF” gene changes. It may help shrink tumors or control cancer growth, and also finds the safest dose and best way to use the drug.
Boston, MassachusettsAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Boston, MassachusettsAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Boston, MassachusettsAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Boston, MassachusettsAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Worcester, MassachusettsAges 18 years+ - NCT07349537RecruitingPhase 1
Study of RMC-5127 for advanced KRAS G12V-mutant solid tumors
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
Boston, MassachusettsAges 18 years+ - NCT06427954Recruiting
Mobile app study for people with advanced lung cancer
This study tests a mobile app (called THRIVE) to help people with advanced lung cancer manage their health and well-being. You'll use the app on your phone to track symptoms and get support, which may help you feel better and stay more in control.
Boston, MassachusettsAges 18 years+ - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06538038Recruiting
Osimertinib plus chemo vs. osimertinib alone for EGFR-mutated NSCLC
This study compares two standard treatments for advanced lung cancer with an EGFR mutation: osimertinib alone versus osimertinib plus chemotherapy. It aims to see which approach works better and is not a trial of a new drug, so you can receive usual care while contributing data.
Lowell, MassachusettsAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Boston, MassachusettsAges 18 years+ - NCT06987890Recruiting
Geriatric assessment for older adults with lung cancer getting SBRT
This study looks at how a geriatric assessment can help older adults with early-stage lung cancer who are getting a precise type of radiation therapy called SBRT. The goal is to understand their needs and improve care.
Boston, MassachusettsAges 65 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Boston, MassachusettsAges 16 years+ - NCT02468024RecruitingPhase 3
Surgery or focused radiation for early lung cancer
This study compares two treatments—removing only part of the lung (sublobar resection) versus a focused radiation approach (stereotactic ablative radiotherapy)—for early-stage non-small cell lung cancer. It aims to see which option works better with fewer problems for the right patients.
Boston, MassachusettsAges 18 years+ - NCT06162221RecruitingPhase 1/Phase 2
Study of RAS inhibitors for advanced RAS-mutated lung cancer
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Boston, MassachusettsAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Boston, MassachusettsAges 18 years+ - NCT06667076RecruitingPhase 2
Amivantamab combinations for advanced EGFR-mutant lung cancer
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Boston, MassachusettsAges 18 years+ - NCT06667908RecruitingPhase 2
Study of a drug with chemoradiation for stage 3 lung cancer
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
Boston, MassachusettsAges 18 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Boston, MassachusettsAges 18 years+
Lung Cancer (NSCLC) trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting lung cancer (nsclc) studies listed above.
- Dana-Farber Cancer Institute · 13 studies
- Massachusetts General Hospital · 11 studies
- Beth Israel Deaconess Medical Center · 4 studies
- Brigham and Women's Hospital · 3 studies
- Boston Medical Center
- Boston University Medical Center
- Lowell General Hosptial
- Mass General Waltham
What taking part in a lung cancer (nsclc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung Cancer (NSCLC) trials in other states
Common questions
- Are there lung cancer (nsclc) clinical trials in Massachusetts?
- Yes. We're currently tracking 109 recruiting lung cancer (nsclc) studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (nsclc) study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (nsclc) studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.